Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small Cajal body specific RNA 11 (SCARNA11) is a non-coding small nucleolar RNA (snoRNA) that localizes to Cajal bodies, subnuclear structures involved in the post-transcriptional modification of spliceosomal small nuclear RNAs (snRNAs)[1]. The gene resides on chromosome 12 at location 8,750,105-8,750,236 (forward strand)[1]. SCARNA11 is annotated as a member of the small cajal body-specific RNAs, specialized in guiding chemical modifications of snRNAs required for proper splicing of pre-mRNA[1]. No therapeutic targeting, disease association, or pharmacological interactions have been reported for SCARNA11 in the biomedical literature. This target is a non-coding RNA and thus is not considered a therapeutic target in the conventional sense of drug discovery (such as receptor, enzyme, transporter). No pharmacological, clinical, or disease-associated relevance is described for SCARNA11 in current resources[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small Cajal body specific RNA 11 (SCARNA11).